Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

摘要: Background Constitutive activation of KIT receptor tyrosine kinase is critical in the pathogenesis gastrointestinal stromal tumors. Imatinib mesylate, a selective inhibitor, has been shown preclinical models and preliminary clinical studies to have activity against such Methods We conducted an open-label, randomized, multicenter trial evaluate imatinib patients with advanced tumor. assessed antitumor response safety tolerability drug. Pharmacokinetics were subgroup patients. Results A total 147 randomly assigned receive 400 mg or 600 daily. Overall, 79 (53.7 percent) had partial response, 41 (27.9 stable disease, for technical reasons, could not be evaluated 7 (4.8 percent). No patient complete treatment. The median duration reached after follow...